Endocrine Abstracts

Introduction: It is well known that the prevalence of major cardiovascular risk factors has increased in HIV-infected people since improvement of antiretroviral therapy. Currently, Spain is defined as a ‘low risk country’ for cardiovascular diseases (CVD) by 2016 European Guidelines on cardiovascular disease prevention. The objective of this study is to assess the prevalence and characteristics of CVD risk factors and risk for CVD in a cohort of HIV-infected adults l...

Introduction: Inhibitors of sodium-dependent glucose co-transporter 2 (SGLT2i) reduce circulating glucose concentrations via a renal mechanism. Its metabolic effects have not been fully described and there is a discrepancy on some clinical results found in studies on SGLT2i. Our aims were to detect if there are some predictor factors to identify what patients will have higher response to dapagliflozin, a SGLT2i, and second, to explore whether intensity of glycosuria is correla...

Introduction: In clinical trials, dapagliflozin has been shown to lower blood glucose, reduce weight and blood pressure in people with type 2 diabetes (T2D). However, there are limited published data on quantitative changes on blood pressure of this drug in routine clinical practice. Our aim was to examine the clinical efficacy of dapagliflozin in patients with T2D and hypertension in a real-life cohort.Methods/design: Prospective study including patient...

Introduction: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are a newly developed class of oral anti-diabetic drugs with a unique mechanism of action and its use is becoming more widespread. Given that dapagliflozin was the first drug of this class used in Spain, available since December 2013, 3 years after its inception, we aimed to investigate whether there have been differences in prescription patterns of SGLT2i (using dapagliflozin as reference) in a Sanitary distric...

Introduction: Pregnancy in a patient with acromegaly is uncommon, as the enlarging pituitary adenoma suppresses gonadotropin secretion rendering the patient amenorrhoeic and infertile. About 40% of the women with pituitary adenomas also have hyperprolactinaemia, which further decreases the likelihood of pregnancy.Case report: A 32-year-old woman was sent to our centre in the first trimester of pregnancy with the diagnostic of gestational diabetes. Clinic...

Introduction: Glucocorticoid resistance syndrome (GRS) is a rare familial or sporadic condition, caused by mutations in glucocorticoid receptor gene. It is characterised by generalised partial resistance of target tissues to cortisol action and compensatory elevation of ACTH with subsequent hypersecretion of cortisol, mineralocorticoids and androgens. Its clinical spectrum is broad and it may occur with high blood pressure (HBP) metabolic alcalosis, hypokalaemia and virilisati...

Introduction: Initial presentation of thyroid carcinoma can range from a solitary thyroid nodule or cervical lymphadenopathy to symptoms related to local compression. Presentation as chylothorax due to compression of thoracic duct is exceptional. The aim of this case report is to describe an extremely rare case of follicular thyroid cancer presenting as chylothorax with special attention to therapeutic aspects.Case report: A 78-years-old woman was referr...

Introduction: The prevalence of metabolic syndrome (MetS) is increasing in patients with HIV infection on highly active antiretroviral therapy (HAART). Additionally, HCV coinfection is common among HIV patients in our area. It is widely known MetS impacts on the liver in different ways but relationship between both MetS and liver function is few studied in HIV/HVC co-infected population.Methods/design: Cross-sectional study including 35 HIV/HVC co-infect...

Introduction: The use of glucagon like peptide 1 analogues (GLP1a) for the treatment of type 2 diabetes mellitus (T2DM) is growing. After a decade-long effort to improve the pharmacokinetics of GLP1, a number of GLP1a are currently available on the market. With a view to identifying patient characteristics that could influence physicians’ prescription of different GLP1a we carried out this observational study in routine clinical practice conditions. Outcomes after add-on ...

Introduction: Multiple studies have evaluated the efficacy of SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1ra) in patients with type 2 diabetes mellitus (T2DM). However, their efficacy in clinical practice is less known in patients receiving insulin and few are the studies that compare use of SGLT2i vs GLP1ra as add-on therapy to insulin. This study aims to assess clinical efficacy of both treatments in a cohort of patients with T2DM on insulin and poor glycemic...